The relation between stereochemistry and biological activity of platinum(II) complexes chelated with chiral diamine ligands: An intricate problem

Current Pharmaceutical Design

Volumn 13, Issue 27, 2007, Pages 2781-2794

  Dufrasne, F ^a   Galanski, M ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Analysis; Bionucleophiles; Cancer; Diaminocyclohexane; Platinum complexes; Stereoisomers; Stereoselectivity

Indexed keywords

ACTIN; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DIAMINE DERIVATIVE; FILAMIN; LA 12; LOBAPLATIN; NEDAPLATIN; OXALIPLATIN; PLATINUM COMPLEX; SATRAPLATIN; SKI 2053; TETRAPLATIN; TRK 710; UNCLASSIFIED DRUG; DIAMINE; LIGAND; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CHIRALITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG CLEARANCE; DRUG DNA INTERACTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; KIDNEY INJURY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; DIAMINES; HUMANS; LIGANDS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35748938791     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781757060     Document Type: Review

References (133)

1. Jenner P, Testa B. The influence of stereochemical factors on drug disposition. Drug Metab Rev 1973; 2: 117-84.
2. Testa B. Chiral aspects of drug metabolism. Trends Pharmacol Sci 1986; 7: 60-4.
3. Beckett AH. Chirality and its importance in drug development: What are the issues? Biochem Soc Trans 1991; 19: 443-6.
4. Caldwell J. The importance of stereochemistry in drug action and disposition. J Clin Pharmacol 1992; 32: 925-9.
5. Caner H, Groner E, Levy L. Trends in the development of chiral drugs. Drug Discov Today 2004; 9: 105-10.
6. Testa B, Mayer JM. In: Eichelbaum M, Testa B, Somogyi A Ed, Handbook of Experimental Pharmacology. Berlin Heidelberg, Springer 2003; 153: 143-59.
7. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. Drugs 2000; 60: 895-924.
8. Galanski M, Jakupec MA, Keppler BK. hi: Pérez JM, Fuertes MA, Alonso C Ed, Metal compounds in cancer chemotherapy. Trivandrum, Research Signpost. 2005; 155-85.
9. Kim D-K, Kim G, Gam J, Cho Y-B, Kim H-T, Tai J-H, et al. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane] Pt(II) complexes. J Med Chem 1994; 37: 1471-85.
10. Jakupec MA, Galanski M, Keppler BK. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev Physiol Bioch P 2003; 146: 1-53.
11. Kido Y, Khokhar AR, Al-Baker S, Siddik ZH. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum(IV) complexes mediated by axial and equatorial ligands. Cancer Res 1993; 53: 4567-72.
12. Epelbaum R, Teicher BA, Holden SA, Ara G, Varshney A, Herman TS. Interaction of D, L- and D-tetraplatin with hyperthermia in vitro and in vivo. Eur J Cancer 1992; 28: 794-800.
13. Anderson WK, Quagliato DA, Haugwitz RD, Narayanan VL, Wolpert-DeFilippes MK. Synthesis, physical properties, and anti-tumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep 1986; 70: 997-1002.
14. Kidani Y, Inagaki K, Tsukagoshi S. Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. Gann 1976; 67: 921-2.
15. Kidani Y, Inagaki K, Iigo M, Hoshi A, Kuretani K. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J Med Chem 1978; 21: 1315-8.
16. Noji M, Okamoto K, Kidani Y, Tashiro T. Relation of conformation to antitumor activity of Pt (II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388. J Med Chem 1981; 24: 508-15.
17. Gullotti M, Pacchioni Q. Pasini A, Ugo R. Complexes of Pt(II) with chiral diamines and guanosines. Stereochemical investigations related to the mechanism of thm antitumor activity of cisbis(amine)Pt(II) type complexes. Inorg Chem 1982; 21: 2006-14.
18. Inagaki K, Kidani Y. Differences in binding of (1,2-cyclohexane-diamine)Pt(II) isomers with d(GpG). Inorg Chem 1986; 25: 1-3.
19. Xu Y, Natile G, Intini FP, Marzilli LG. Stereochemically controlled ligands influence atropisomerization of Pt(II) nucleotide complexes. Evidence for head-to-head and stable head-to-tail atropisomers. J Am Chem Soc 1990; 112: 8177-9.
20. Hambley TW. The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coordin Chem Rev 1997; 166: 181-223.
21. Benedetti M, Malina J, Kasparkova J, Brabec V, Natile G. Chiral discrimination in pratinum anticancer drugs. Environ Health Persp 2002; 110: 779-82.
22. 2 complexes. Dalton Trans 2003; 872-9.
23. Kidani Y, Noji M, Tashiro T. Antitumor activity of platinum(II), complexes of 1,2-diaminocyclohexane isomers. Gann 1990; 71: 637-43.
24. Siddik ZH, Al-Baker S, Thai G, Khokhar AR. Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes. J Cancer Res Clin Oncol 1994; 120: 409-14.
25. Siddik ZH, Al-Baker S, Burditt TL, Khokhar AR. Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes. J Cancer Res Clin Oncol 1993; 120: 12-6.
26. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99: 2467-98.
27. Kozubik A; Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, et al. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 2005; 69: 373-83.
28. Kelland LR. In: LipCert B Ed, Cisplatin: chemistry and biochemistry of a leading anticancer drugs. Zürich, Wiley-VCH. 1999; 497-521.
29. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000; 59(S4): 19-27.
30. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. In: Hardman JG, Limbird LE Ed, The pharmacological basis of therapeutics. New York, McGraw-Hill. 2001; 1432-5.
31. Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 2002; 62: 1154-9.
32. Nitiss JL. A copper connection to the uptake of platinum anticancer drugs. Proc Natl Acad Sci USA 2002; 99: 13963-5.
33. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002; 99: 14298-302.
34. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishimaet M, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002; 62: 6559-65
35. Gullotti M, Pasini A, Ugo R, Filippeschi S, Marmonti L, Spreafico F. Enantiomeric cisplatin analogues: An investigation on their activity towards tumors in mice. Inorg Chim Acta 1984; 91: 223-7.
36. Noji M, Motoyama S, Tashiro T, Kidani Y. Synthesis and antitumor activity of platinum (II) complexes containing 2,3-diaminopropanol isomers. Chem Pharm Bull 1983; 31: 1469-73.
37. Büning H, Altman J, Zorbas H, Beck W. Bis[Pt(II)] and bis [Pt(IV)] complexes with optically active bis (vicinal-1,2-diamines) and their interaction with DNA. J Inorg Biochem 1999; 75: 269-79.
38. Hanessian S, Wang J. Hydrophilic analogs of (R,R)-diaminocyclohexane dichloroplatinum (DACH) and the influence of relative stereochemistry on antitumor activity. Can J Chem 1993; 71: 2102-8.
39. Morikawa K, Honda M, Endoh K-I, Matsumoto T, Akamatsu K-I, Mitsui H, et al. Synthesis, antitumor activity, and nephrotoxicity of the optical isomers of 2-aminomethylpyrrolidine(1,1-cyclobutane-dicarboxylato)platinum(II). J Pharm Sci 1991; 80: 837-42.
40. Fenton RR, Easdale WJ, Er HM, O'Mara S, McKeage MJ, Russell PJ, et al. Preparation, DNA binding, and in vitro cytotoxicity of pair of enantiomeric Pt(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloro Pt(II). Crystal structure of the S enantiomer. J Med Chem 1997; 40: 1090-8.
41. Rezler EM, Fenton RR, Easdale WJ, McKeage MJ, Russell PJ, Hambley TW. Preparation, characterization, DNA binding, and in vitro cytotoxicity of the enantiomers of the platinum(II) complexes N-methyl-, N-ethyl- and N,N-dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II). J Med Chem 1997; 40: 3508-15.
42. Brunner H, Hankofer P, Holzinger U, Treittinger B, Schönenberger H. Synthesis and antitumor activity of platinum (II) complexes containing substituted ethylenediamine ligands. Eur J Med Chem 1990; 25: 35-44
43. vom Orde HD, Reile H, Müller R, Gust R, Bernhardt G, Spruss T, et al. Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes. J Cancer Res Clin Oncol 1990; 116: 434-8.
44. Wappes B, Jennerwein M, von Angerer E, Schönenberger H, Engel J, Berger M, et al. Dichloro-[1,2-bis-(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: An approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma. J Med Chem 1984; 27: 1280-6
45. Bernhardt G, Gust R, Reile H, vom Orde HD; Müller R, Keller C, et al. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum (II), a new compound for the therapy of ovarian cancer. J Cancer Res Clin Oncol 1992; 118: 209-15.
46. Jennerwein M, Gust R, Müller R, Schönenberger H, Engel J, Berger MR, et al. Tumor inhibiting properties of stereoisomeric [1,2-Bis(3-hydroxyphenyl)ethylenediamine] dichloroplatinum (II)-complexes. Part II: Biological properties. Arch Pharm 1989; 322: 67-73.
47. Gust R, Gelbcke M, Angermaier B, Bachmann H, Krauser R, Schönenberger H. The stereoselectivity of antitumor active 1,2-diamino-1-phenylpropanedichloroplatinum (II) complexes. Inorg Chim Acta 1997; 264: 145-60.
48. Dufrasne F, Gelbcke M, Schnurr B, Gust R. Synthesis and antitumor activity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)propane]dichloroplatinum(II) complexes. Arch Pharm 2002; 335: 229-39.
49. Dullin A, Dufrasne F, Gelbcke M, Gust R. Enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: Synthesis and antitumor activity against MCF-7 and MDA-MB-231 breast cancer and LnCaP/FGC prostate cancer cell lines. Arch Pharm 2004; 337: 654-67.
50. Okamoto K, Noji M, Tashiro T, Kidani Y. Preparation of platinum(II) complexes of diamine isomers [PtX(1,3-diamine)](X = dichloro, sulfato, dinitrato, oxalato, D-glucuronato, and D-gluconato) and determination of their antitumor activity against leukemia L1210. Chem Pharm Bull 1981; 29: 929-39.
51. Vickery K, Bonin AM, Fenton RR, O'Mara S, Russell PJ, Webster LK, et al. Preparation, characterization, cytotoxicity, and mutagenicity of a pair of enantiomeric Pt(II) complexes with the potential to bind enantioselectively to DNA. J Med Chem 1993; 36: 3663-8.
52. 2Pt(II) complexes. J Med Chem 1989; 32: 214-7.
53. Witiak DT, Rotella DP, Wie Y, Filppi JA, Gallucci JC. Stereo-controlled syntheses for the six diastereoisomeric 1,2-dihydroxy-4,5-diaminocyclohexanes: Pt(II) complexes and P-388 antitumor properties. J Med Chem 1987; 30: 1327-36.
54. Reile H, Spruss T, Bernhardt G, Müller R, Gust R, Schönenberger H. Tumor inhibiting [1,2-Bis(fluorophenyl)ethylenediamine]platinum(II) complexes:PArt 4: biological evaluation - in vivo studies on the P 388 leukemia. Arch Pharm 1991; 324: 405-9.
55. Vollano JF, Al-Baker S, Dabrowiak JC, Schurig JE. Comparative studies on platinum (II) and platinum (IV) complexes containing 1,2-diaminocyclohexane. J Med Chem 1987; 30: 716-9.
56. Gust R, Schönenberger H. Synthesis an evaluation of the anti-mammary tumor activity and of the estrogenic side effects of [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine] platinum (II) complexes. Eur J Med Chem 1993; 28: 103-15.
57. Bernhardt G, Koch M, Spruss T, Gust R, Krauser R, Schlemmer R, et al. [Meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]sulfato platinum (II) - pharmacokinetic studies. Arch Pharm Pharm Med Chem 1999; 332: 195-200.
58. Zlatanova J, Yaneva J, Leuba SH. Proteins that specifically recognize cisplatin-damaged DNA: A clue to anticancer activity of cisplatin. FASEB J 1998; 12: 791-9.
59. 14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol 2004; 66: 789-93.
60. Rosenberg B. In: LiCpert B Ed, Cisplatin: chemistry and biochemistry of a leading anticancer drugs. Zürich, Wiky-VCH. 1999; 3-27.
61. Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 1995; 377: 649-52.
62. Gelasco A, Lippard SJ. NMR Solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) D(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 1998; 37: 9230-9.
63. Wu Y, Pradhan P, Havener J, Boysen G, Swenberg JA, Campbell SL, et al. NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J Mol Biol 2004; 341: 1251-69
64. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M, Brabec V. Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 1992; 20: 267-72.
65. Murray V, Whittaker J, Temple MD, McFadyen WD. Interaction of 11 cisplatin analogs with DNA: Characteristic pattern of damage with monofunctional analogs. Biochim Biophys Acta 1997; 1354: 261-71.
66. Miller KJ, McCarthy SL, Krauss M. Binding of cis-(1,2-diaminocyclohexane) platinum (II) and its derivatives to duplex DNA. J Med Chem 1990; 33: 1043-6.
67. Morikawa K, Matsumoto T, Matsuoka Y, Koizumi M. The interactions of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato) Pt(II) monohydrate (DWA2114R) and related compounds with deoxyribonucleic acid. Chem Pharm Bull 1992; 40: 212-9.
68. Pasini A, Velcich A, Mariani A. Absence of diastereoisomeric behaviour in the interaction of chiral platinum anticancer compounds with DNA. Chem Biol Interact 1982; 42: 311-20.
69. Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane-platinum(II) complexes. Chem Biol Interact 1989; 70: 39-49.
70. Marzilli LG, Intini FP, Kiser D, Wong HC, Ano SO, Marzilli PA, et al. Chirality-Controlling Chelate (CCC) ligands in analogs of platinum anticancer agents. Influence of N9 substituents of guanine derivatives (G) on the distribution of chiral conformers of (CCC)PtG2 with CCC = NN'-dimethyl-2,3-diaminobutane. Inorg Chem 1998; 37: 6898-905.
71. 2 complexes. Inorg Chem 1999; 38: 2989-99.
72. Malina J, Hofr C, Maresca L, Natile G, Brabec V. DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands. Biophys J 2000; 78: 2008-21.
73. Malina J, Kasparkova J, Natile G, Brabec V. Recognition of major DNA adducts of enantiomeric cisplatin analogs by HGM Box proteins and nucleotide excision repair of these adducts. Chem Biol 2002; 9: 629-38.
74. Malina J, Vojtiskova M, Brabec V, Diakos CI, Hambley TW. DNA adducts of the enantiomers of the Pt(II) complexes of the ahaz ligand (ahaz = 3-aminohexahydroazepine) and recognition of these adducts by HMG domain proteins. Biochem Biophys Res Commun 2005; 332: 1034-41.
75. Monti E, Gariboldi M, Maiocchi A, Marengo E, Cassino C, Gabano E, et al. Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: A quantitative structure-activity relationship approach. J Med Chem 2005; 48: 857-66
76. Lin T-S, Zhou R-X, Scanlon KJ, Brubaker WF, Lee JJS, Woods K, et al. Synthesis and biological activity of several amino nucleoside-platinum (II) complexes. J Med Chem 1986; 29: 681-6.
77. Ho Y-P, Au-Yeung SCF, To KKW. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 2003; 21: 633-55.
78. Galanski M, Slaby S, Jakupec MA, Keppler BK. Synthesis, characterization, and in vitro antitumor activity of osteotropic diam(m) ineplatinum(II) complexes bearing a N,N-bis(phosphonomethyl) glycine ligand. J Med Chem 2003; 46: 4946-51.
79. Paschke R, Paetz C, Mueller T, Schmoll HJ, Mueller H, Sorkau E, et al. Biomolecules linked to transition metal complexes - New chances for chemotherapy. Curr Med Chem 2003; 10: 2033-44.
80. Gust R, Niebler K, Schönenberger H. Investigation of the configurational and conformational influences on: The hormonal activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes. 1. Synthesis, estradiol receptor affinity, and estrogenic activity of diastereomeric [N-alkyl- and N,N'-dialkyl-1,2-bis (2,6-dichloro-4-hydroxyphenyl)ethylenediamine]-dichloroplatinum (II) complexes. J Med Chem 1995; 38: 2070-9.
81. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 2000; 6: 1205-18.
82. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6.
83. Samimi G, Safaei R, Katano R, Holzer AK, Rochdi M, Tomioka M, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004; 10: 4661-9.
84. Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, et al. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 2004; 53: 239-46.
85. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homplogues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57: 3537-47.
86. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma tells-resistant to cisplatin. J Investig Dermatol 2003; 121: 172-6.
87. Song I-S, Savaraj N, Siddik ZH, Liu P, Wie Y, Wu CJ, et al. Role of human copper transporter Ctrl in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004; 3: 1543-9.
88. Paolicchi A, Sotiropuolou M, Perego P, Daubeuf S, Visvikis A, Lorenzini A, et al. γ-glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in human cell line derived from the proximal convoluted tubule of the kidney. Eur J Cancer 2003; 39: 996-1003.
89. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14: 1-10.
90. Ludwig T, Rieth,üller C, Gekle M, Schwerdt G, Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004; 66: 196-202.
91. Fakih S, Munk VP, Shipman MA, Murdoch PDS, Parkinson PA, Sadler PJ. Novel adducts of the anticancer drug oxaliplatin with glutathione and redox reactions with glutathione disulfide. Eur J Inorg Biochem 2003; 1206-14.
92. Jansen BAJ, Brouwer J, Reedijk J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem 2002; 89: 197-202.
93. Natarajan G, Malathi R, Holler E. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: Activation theory revisited. Biochem Pharmacol 1999; 58: 1625-29.
94. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair'pathway in ovarian cancer cell lines. Cancer Res 2003; 63; 1311-6.
95. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-5.
96. Saga Y, Hashimoto H, Yachiku S, Iwata T, Tokumitsu M. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Int J Urol 2004; 11: 4107-15.
97. Zhang L, Hanigan MH. Role of cystein S-conjugate β-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther 1996; 306: 988-94.
98. Vrana O, Brabec V. L--methionine inhibits reaction of DNA with anticancer cis-diamminedichloroplatinum (II). Biochemistry 2002; 41: 10994-9.
99. El-Khateeb M, Appleton TG, Gahan LR, Charles BG, Berners-Price SJ, Bolton A-M. Reactions of hydrolytes with methionine, cysteine, and plasma, ultrafiltrate studied by a combination of HPLC and NMR techniques. J Inorg Biochem 1999; 77: 13-21.
100. Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven PJ. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 1995; 97: 177-84.
101. Lindauer E, Holler E. Cellular distribution and cellular reactivity of platinum (II) complexes. Biochem Pharmacol 1996; 52: 7-14.
102. Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W, McKeage MJ. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 1997; 76: 502-10.
103. Guo Y, Smith K, Petris MJ. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter. J Biol Chem 2004; 279: 46393-9.
104. Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003; 63: 312-8.
105. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313-20.
106. Boubakari, Bracht K, Neumann C, Grünert R, Bednarski PJ. No correlation between GSH level in human cancer cell lines and the cell growth inhibitory activities of platinum diamine complexes. Arch Pharm, 2004; 337: 668-71.
107. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003; 66: 225-37.
108. Rosenhagen MC, Soti C, Schmidt U, Wochnik GM, Hartl FU, Holsboer F, et al. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol 2003; 17: 1991-2001.
109. Colangelo D, Ghiglia AL, Viano I, Mahboobi H, Ghezzi A, Cassino C, et al. Might telomerase enzyme be a possible target for trans-Pt(II) complexes? J Inorg Biochem 2004; 98: 61-7.
110. Colangelo D, Osella D. Telomerase Ulhibition and cancer: Might platinum based drugs have a future as anti-telomerase pharmacological approach? Curr Med Chem 2005; 12: 3091-102.
111. 3H-isoquinoline) complex, a selective inhibitor of telomerase enzyme. Biometals 2003; 16: 553-60
112. Fujie Y, Yamamoto H, Ngan CY, Akimitsu T, Hayashi T, Suzuki R et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005; 35: 453-63.
113. Reile H, Müller R, Gust R, Laske R, Krischke W, Bernhardt W et al. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum (II) complexes. Part II: Biological evaluation - in vitro studies on the P388 D1 leukemia cell line. Arch Pharm 1990; 323: 133-40.
114. Bednarski PJ. Reactions of a cisplatin analog bearing an estrogenic 1,2-diarylethylenediamine ligand with sulfur-containing amino acids and glutathione. J Inorg Biochem 1995; 80: 1-19.
115. Chen Y, Guo Z, Sadler PJ. In: Lippert B Ed, Cisplatin chemistry and biochemistry of a leading anticancer drug. Zürich, Wiley-VCH. 1999; 293-318.
116. Huang. H, Zhu L. Reid BR, Drobny GP, Hopkins PB. Solution, structure of a cisplatin-induced DNA interstrand cross-link. Science 1975; 270: 1842-5.
117. Chen Y, Guo Z, Parsons S, Sadler PJ. Stereospecific and kinetic control over the hydrolysis of a sterically hindered platinum picoline anticancer complex. Chem Eur J 1998; 4: 672-6.
118. 31P shift and potential hydrogen-bonding interactions in pGpG moieties cross-linked by platinum. Inorg Chem 1988; 27: 366-76.
119. Appleton TG, Connor JW, Hall JR, Prenzler PD. S,O- versus S,N-chelation in the reactions of the cis-diamminediaquaplatinum(II) cation with methionine and S-methylcysteine. Inorg Chem 1989; 28: 2030-7.
120. Barefoot RR. Speciation of platinum compounds: A review of recent applications in studies of platinum anticancer drugs. J Chromatogr B 2001; 751: 205 -11.
121. Hagrman D, Goodisman J, Souid A-K. Kinetic study on the reactions of platinum drugs with glutathione. J Pharmacol Exp 2004; 308: 658-66.
122. Luo FR, Yen T-Y, Wyrick SD, Chaney SG. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J Chromatogr B 1999; 724: 345-56.
123. Hagrman H, Goodisman J, Dabrowiak JC, Souid A-K. Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab Dispos 2003; 31: 916-23.
124. Townsend DM, Marto JA, Deng M, Macdonald TJ, Hanigan ME. High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of cisplatin. Drug Metab Dispos 2003; 31: 705-13.
125. Miao R, Yang G, Miao Y, Mei Y, Hong J. Zhao C, et al. Interaction of platinum(II) complexes with sulfur-containing peptides studied by electrospray ionization mass spectrometry and tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 1031-40.
126. 2] with γ-glutathione and L-cysteine. J Inorg Biochem 2004; 98: 702-12.
127. Hartinger CG, Timerbaev AR, Keppler BK. Capillary electrophoresis in anti-cancer metallodrug research: Advances and future challenges. Electrophoresis 2003; 24: 2023-37.
128. Rudnev AV, Aleksenko SS, Semenova O, Hartinger CG, Timerbaev AR, Keppler BK. Determination of binding constants and stoechiometries for platinum anticancer drugs and serum proteins by capillary electrophoresis using the Hummel-Dreyer method. J Sep Sci 2005; 28: 121-7.
129. Küng A, Strickmann DB, Galanski M, Keppler BK. Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5′-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. J Inorg Biochem 2001; 86: 691-8.
130. Rappel C, Galanski M, Yasemi A, Habala L, Keppler BK. Analysis of anticancer platinum(II)-complexes by microemulsion electrokinetic chromatography: Separation of diastereoisomers and estimation of octanol-water partition coefficients. Electrophoresis 2005; 26: 878-84.
131. Altmann KH. Recent developments in the chemical biology of epothilones. Curr Pharm Des 2005; 11(13): 1595-613.
132. Uccello-Barretta G, Balzano F, Salvadori P. Enantiodiscrimination by NMR spectroscopy. Curr Pharm Des 2006; 12(31) 4023-45.
133. Watkins EB, Chittiboyina AG, Jung JC, Avery MA. The epothilones and related analogues-a review of their syntheses and anti-cancer activities. Curr Pharm Des 2005; 11(13): 1615-53.